Marchex Reports Q4 Results, Projects 2026 Growth, and Provides Key Update on Archenia Acquisition
MCHX is trading near its 52-week low of $1.26 (12% above the low) on light trading volume (0.4× avg).
Summary
Marchex reported a decline in Q4 and full-year 2025 revenue and increased losses, but provided strong 2026 guidance projecting a return to profitability and growth, alongside a material update on its proposed acquisition of Archenia, Inc., which is expected to significantly boost combined revenue and EBITDA.
Key Events · M&A and Partnerships · MCHX
-
Q4 and Full Year 2025 Financial Results
Marchex reported GAAP revenue of $10.8 million for Q4 2025 (down from $11.9 million in Q4 2024) and $45.4 million for full year 2025 (down from $48.1 million in 2024). Net loss increased to $2.3 million in Q4 2025 and $5.2 million for the full year 2025.
-
Positive 2026 Financial Outlook
The company anticipates Q1 2026 revenue to be at Q4 2025 levels, with Adjusted EBITDA of $500,000 or more. For Q2 2026, revenue is expected to increase sequentially, with Adjusted EBITDA potentially exceeding $1 million. Marchex projects sequential quarterly revenue increases throughout 2026, aiming for a 10% run rate growth from 2025 year-end levels and Adjusted EBITDA margins of 10% or more.
-
Material Update on Archenia Acquisition
Marchex provided an update on its Agreement in Principle to acquire Archenia, Inc., anticipating a closing in June 2026, subject to disinterested stockholder approval. Archenia estimates over $17 million in revenue and positive Adjusted EBITDA for 2025. The combined company is projected to achieve approximately $60 million in annualized revenue with 15-20% growth and 10%+ Adjusted EBITDA margins, significantly expanding Marchex's market and capabilities.
Analysis · MCHX · Technology
This filing presents a mixed financial picture for Marchex, with a decline in Q4 and full-year 2025 revenue and increased net losses. However, the forward-looking guidance is significantly positive, projecting a return to positive Adjusted EBITDA in Q1 2026 and sequential revenue growth throughout the year, aiming for a 10% run rate increase from 2025 levels. Crucially, the update on the proposed acquisition of Archenia, Inc. is highly material. Archenia's estimated 2025 revenue of over $17 million and positive Adjusted EBITDA would be substantially accretive to Marchex, potentially boosting the combined company's annualized revenue to approximately $60 million with 15-20% growth and 10%+ Adjusted EBITDA margins. This acquisition, if approved by disinterested stockholders and closed by June 2026, represents a significant strategic pivot and growth catalyst for Marchex, transforming its financial profile and market position.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCHX was trading at $1.41 on NASDAQ in the Technology sector, with a market capitalization of approximately $65.4M. The 52-week trading range was $1.26 to $2.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.